Will the 'patent dance' cause Amgen to pull a biosimilar off the market?

Will the 'patent dance' cause Amgen to pull a biosimilar off the market?

STAT Plus: Will the ‘patent dance’ cause Amgen to temporarily pull a biosimilar off the market?

By ED SILVERMAN

RUBY WALLAU FOR STAT

In a closely watched case, a federal appeals court must decide whether a biosimilar company should temporarily pull its product off the market.

READ MORE